AbbVie director awarded 1,118 restricted stock units

FREYMAN THOMAS C reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

FREYMAN THOMAS C reported acquisition or exercise transactions in this Form 4 filing.

AbbVie Inc. director Thomas C. Freyman received a grant of 1,118 restricted stock units of AbbVie common stock at a stated price of $0.00 per share. After this award, he directly holds 127,869 shares of AbbVie common stock.

The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be paid one-for-one in AbbVie shares upon the earlier of his separation from service, death, or a defined change in control. Additional AbbVie shares are held in trusts for his spouse and son, totaling 1,941 shares and 4,000 shares respectively, for which he disclaims beneficial ownership.

Insider Trade Summary

Grant/Award: 1,118 shares

Grant/Award 4 txns

Insider FREYMAN THOMAS C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.01 par value	1,118	$0.00	$0.00
holding	Common Stock, $0.01 par value	--	--	--
holding	Common Stock, $0.01 par value	--	--	--
holding	Common Stock, $0.01 par value	--	--	--

Holdings After Transaction: Common Stock, $0.01 par value — 127,869 shares (Direct); Common Stock, $0.01 par value — 4,000 shares (Indirect, By spouse in trust); Common Stock, $0.01 par value — 3,882 shares (Indirect, By spouse in trust for son)

Footnotes (3)

1. F1. These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
2. F2. The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
3. F3. Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities.

Key Figures

RSU grant size: 1,118 units Grant price per share: $0.00 per share Direct holdings after grant: 127,869 shares +2 more

5 metrics

RSU grant size 1,118 units Restricted stock units awarded to director

Grant price per share $0.00 per share Stated price for RSU-related common stock

Direct holdings after grant 127,869 shares AbbVie common stock held directly post-transaction

Spouse trust holdings 1,941 shares Shares held by spouse in trust for son; beneficial ownership disclaimed

Irrevocable trust holdings 4,000 shares Shares held in irrevocable trust for son; beneficial ownership disclaimed

Key Terms

restricted stock units, AbbVie Amended and Restated 2013 Incentive Stock Program, change in control, beneficial ownership

4 terms

restricted stock units financial

"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AbbVie Amended and Restated 2013 Incentive Stock Program financial

"awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program")"

change in control financial

"on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

beneficial ownership financial

"The reporting person disclaims beneficial ownership of these securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

What insider transaction did AbbVie (ABBV) director Thomas C. Freyman report?

Thomas C. Freyman reported receiving 1,118 restricted stock units of AbbVie common stock as a grant. The units were awarded at a stated price of $0.00 per share under AbbVie’s 2013 Incentive Stock Program, reflecting routine director equity compensation.

How many AbbVie (ABBV) shares does Thomas C. Freyman hold after this Form 4?

Following the reported grant, Thomas C. Freyman directly holds 127,869 shares of AbbVie common stock. This figure reflects his direct ownership only and excludes shares held in separate family trusts where he has disclaimed beneficial ownership.

When will Thomas C. Freyman’s AbbVie restricted stock units be paid out?

The 1,118 restricted stock units will be paid one-for-one in AbbVie common shares on the earlier of his separation from service, death, or a defined change in control. These payout conditions are set by AbbVie’s Amended and Restated 2013 Incentive Stock Program.

What is the role of trusts in Thomas C. Freyman’s AbbVie (ABBV) holdings?

AbbVie shares are also held in trusts benefiting his spouse and son, with 1,941 shares and 4,000 shares reported. His spouse serves as trustee, and the filing states that Freyman disclaims beneficial ownership of these trust-held securities.

Is the AbbVie (ABBV) Form 4 transaction a market purchase or sale?

No market purchase or sale is reported. The Form 4 shows a grant of 1,118 restricted stock units at a stated price of $0.00 per share, categorized as a grant or award acquisition rather than an open-market buy or sell transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FREYMAN THOMAS C

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	05/08/2026		A		1,118(1)	A	$0	127,869	D
Common Stock, $0.01 par value								4,000(2)	I	By spouse in trust
Common Stock, $0.01 par value								1,941(3)	I	By spouse in trust for son
Common Stock, $0.01 par value								1,941(3)	I	By spouse in trust for son

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

2. The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.

3. Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities.

	/s/ T.O. Odutayo, attorney-in-fact for Thomas C. Freyman	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)